NKG2D

NKG2D Informations sur la molécule

Nom anglais	NKG2-D type II integral membrane protein	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	9	Alias de la cible	Killer cell lectin-like receptor subfamily K member 1，NK cell receptor D，NKG2-D-activating NK receptor，CD314，D12S2489E，KLR，DNA Segment On Chromosome 12 (Unique) 2489 Expressed Sequence，Killer Cell Lectin Like Receptor K1，NKG2-D，Killer Cell Lectin-Like Receptor Subfamily K， Member 1，KLRK1，CD314 Antigen
Phase de R&D la plus avancée	Phase 2 Clinical

Nom anglais	NKG2-D type II integral membrane protein
Alias de la cible	Killer cell lectin-like receptor subfamily K member 1，NK cell receptor D，NKG2-D-activating NK receptor，CD314，D12S2489E，KLR，DNA Segment On Chromosome 12 (Unique) 2489 Expressed Sequence，Killer Cell Lectin Like Receptor K1，NKG2-D，Killer Cell Lectin-Like Receptor Subfamily K， Member 1，KLRK1，CD314 Antigen
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	9
Phase de R&D la plus avancée	Phase 2 Clinical

NKG2D Liste de produits

Attribut
Protein (7)
Bibliothèque de produits
En ligne (7)
Espèces
Human (6)Cynomolgus (1)
Étiquette
Fc Tag (2)His Tag (2)Mouse IgG Fc Tag (1)Avi Tag & Fc Tag (1)His Tag & Avi Tag (1)
Marqueur
Unconjugated (4)FITC Labeled (1)Biotin-labeled (2)

Numéro de produit	Espèces	Système d'expression	Description du produit	Pré-commande/Commande
HOT NKD-H5245	Human	HEK293	Human NKG2D / CD314 Protein, His Tag, low endotoxin (HPLC verified)	Ajouter au panier
HOT NKD-H5259	Human	HEK293	Human NKG2D / CD314 Protein, Mouse IgG2a Fc Tag	Ajouter au panier
HOT NKD-H5265	Human	HEK293	Human NKG2D / CD314 Protein, Fc Tag (MALS verified)	Ajouter au panier
HOT NKD-H82Q3	Human	HEK293	Biotinylated Human NKG2D / CD314 Protein, Avitag™,His Tag (MALS verified)	Ajouter au panier
HOT NKD-C5248	Cynomolgus	HEK293	Cynomolgus NKG2D / CD314 Protein, His Tag, low endotoxin	Ajouter au panier
NKD-H82F4	Human	HEK293	Biotinylated Human NKG2D / CD314 Protein, Avitag™,Fc Tag (MALS verified)	Ajouter au panier
NKD-HF224	Human	HEK293	FITC-Labeled Human NKG2D / CD314 Protein, Fc Tag	Ajouter au panier

Quantité totale7

NKG2DContexte de la molécule

NKG2D is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors, also known as KLRK1, CD314, D12S2489E, KLR and killer cell lectin like receptor K1. NKG2D itself forms a homodimer whose ectodomains serve for ligand binding. NKG2D is a major recognition receptor for the detection and elimination of transformed and infected cells as its ligands are induced during cellular stress, either as a result of infection or genomic stress such as in cancer. In NK cells, NKG2D serves as an activating receptor, which itself is able to trigger cytotoxicity. The function of NKG2D on CD8+ T cells is to send co-stimulatory signals to activate them.

NKG2DAlias de la molécule

NKG2D,CD314,KLRK1,NK cell receptor D

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Tesnatilimab	IPH-2301; IPH-23XX; JNJ-4500; JNJ-64304500; NNC-0142-002; NNC-0142-0002; NNC-0142-0000-0002; NN-8555	Phase 2 Clinical	Innate Pharma	Alopecia Areata; Arthritis, Rheumatoid; Celiac Disease; Crohn Disease; Inflammation	Details
NKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology)		Phase 2 Clinical	Chongqing Sidemu Biotechnology Technology Co Ltd	Coronavirus Disease 2019 (COVID-19); Hematologic Neoplasms	Details
NKG2D CAR-T Cell		Phase 1 Clinical	Hangzhou Cheetah Cell Therapeutics Co Ltd	Colorectal Neoplasms; Leukemia, Myeloid, Acute; Neoplasm Metastasis; Ovarian Neoplasms	Details
anti-NKG2D CAR NK-cell therapy (Xinxiang Medical University)		Phase 1 Clinical	Xinxiang Medical University	Solid tumours	Details
Anti-NKG2D CAR-NK cells therapy (CNK Cell Therapeutics)		Phase 1 Clinical	CNK Cell Therapeutics Co Ltd	Solid tumours	Details
Anti-NKG2D CAR-T cell therapy (CNK Cell Therapeutics)		Phase 1 Clinical	Hangzhou CNK Therapeutics Co Ltd	Pancreatic Neoplasms; Solid tumours	Details
NKG2D CAR-T Cell therapy (Yake Biotechnology)		Phase 1 Clinical	Shanghai YaKe Biotechnology Co Ltd	Colorectal Neoplasms; Leukemia, Myeloid, Acute	Details
Anti-NKG2D chimeric antigen receptor natural killer cell therapy (Hangzhou Cheetah Cell Therapeutics)		Clinical		Leukemia, Myeloid, Acute; Ovarian Neoplasms	Details
NKG2D CAR-T cell therapy (Uwell Biopharma)	UWN2D	Clinical	Uwell Biopharma	Neoplasms	Details